- Jul 27, 2013
- 12,092
- 14,916
Hide Ya Wives, Hide Ya Kids: Worldwide Coronavirus Pandemic!
yobyellav
formerly cord15
- Sep 12, 2006
- 12,938
- 9,820
The school district my old high school in cancelled all sports. The local private school has offered some players scholarships. 
rolleyes
rolleyes
- Mar 30, 2007
- 151,226
- 202,662
- Jan 11, 2014
- 8,617
- 17,196
Clinicaltrials.gov
A ph1 in a CRU can sometimes pay well, all things considered.
- Mar 27, 2004
- 18,386
- 34,061
Local hospital put out an ad looking for volunteers for a covid vaccine. I might sign up. If it actually confers immunity, that's pretty sweet.
- Dec 9, 2002
- 34,659
- 28,018
Adults aren't even behaving.
- May 3, 2009
- 10,298
- 26,749
- Mar 30, 2007
- 151,226
- 202,662
- Jan 11, 2015
- 1,795
- 3,112
- Jul 29, 2012
- 4,736
- 5,521
When it comes to paying taxes:
Church - "We're not a business, we're are religious organization, so no taxes."
When it comes to getting relief for businesses:
Church -"We're a business. Still not paying taxes though"
From the constitution - first amendment:
"Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof". 10,000,000,000$ is pretty respectful
- Aug 5, 2007
- 16,551
- 21,154
this is the dumb **** i’m talking about man. who the **** would think a hot yoga class would be ok?!
- Jul 27, 2013
- 12,092
- 14,916
- Jul 22, 2015
- 3,043
- 7,177
- Jul 18, 2012
- 12,997
- 5,248
- Jul 27, 2013
- 12,092
- 14,916
- Jul 27, 2013
- 12,092
- 14,916
- Jul 27, 2013
- 12,092
- 14,916
JPMorgan upgrades Novavax on potential 'best-in-class' COVID vaccine
JPMorgan analyst Eric Joseph upgraded Novavax to Overweight from Neutral with a price target of $275, up from $105. The stock in premarket trading is up 17%, or $26.83, to $184.00. The analyst is "pleasantly impressed" by last night's initial immunogenicity/safety profile for NVX-CoV2373 in the Phase 1 COVID-19 vaccine results. It is "not too far a stretch" to conclude the activity of NVX-CoV2373 "looks best-in-class," particularly when anchored to one of the more "stringent" human convalescent sera cohorts reported to date, Joseph tells investors in a research note. On safety, the analyst views the tolerability profile of both doses "as comfortably within the bounds of licensure-eligible candidate." He believes "relative valuations" favor Novavax over the near-term ahead of the first of the competitor Phase 3 COVID-19 vaccine efficacy readouts.
JPMorgan analyst Eric Joseph upgraded Novavax to Overweight from Neutral with a price target of $275, up from $105. The stock in premarket trading is up 17%, or $26.83, to $184.00. The analyst is "pleasantly impressed" by last night's initial immunogenicity/safety profile for NVX-CoV2373 in the Phase 1 COVID-19 vaccine results. It is "not too far a stretch" to conclude the activity of NVX-CoV2373 "looks best-in-class," particularly when anchored to one of the more "stringent" human convalescent sera cohorts reported to date, Joseph tells investors in a research note. On safety, the analyst views the tolerability profile of both doses "as comfortably within the bounds of licensure-eligible candidate." He believes "relative valuations" favor Novavax over the near-term ahead of the first of the competitor Phase 3 COVID-19 vaccine efficacy readouts.
- Jul 27, 2013
- 12,092
- 14,916
- Jul 27, 2013
- 12,092
- 14,916
- Jul 27, 2013
- 12,092
- 14,916
- Oct 28, 2013
- 42,734
- 178,545
- Oct 28, 2013
- 42,734
- 178,545
- Jul 27, 2013
- 12,092
- 14,916
- Oct 28, 2013
- 42,734
- 178,545
- Jan 26, 2003
- 7,480
- 12,521
Lol. Reminds me of "There's 2 types of people in this world. Those that can extrapolate data from incomplete data sets."
